| treatment |
|
comparator |
Serious adverse event | death (overall survival) | progression or death (progression free survival PFS) | objective response (ORR) | progression (Time to progression TTP) | clinical benefit |
|
|
| Sorafenib | advanced breast cancer (metastatic), in all type of patients | vs capecitabine alone | - | NS | by 42% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.86 [0.61 1.22] | p=1.00 | 0 | -18 | 1 | Baselga, | | progression or death (progression free survival PFS) | 0.58 [0.41 0.82] | p=0.04 | 0 | -18 | 1 | Baselga, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Baselga, 2012 | - or second-line capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle with sorafenib 400 mg orally twice a day | capecitabine alone | HER2-negative locally advanced or metastatic breast cancer |
|
| Sorafenib | advanced breast cancer (metastatic), in all type of patients | vs gemcitabine or capecitabine alone | - | NS | by 36% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.01 [0.71 1.44] | p=1.00 | 0 | -18 | 1 | Schwartzberg, | | progression or death (progression free survival PFS) | 0.64 [0.44 0.93] | p=0.04 | 0 | -18 | 1 | Schwartzberg, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Schwartzberg, 2013 | sorafenib (400 mg, twice daily) | placebo | patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab |
|
| Sorafenib | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel alone | - | NS | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.02 [0.71 1.46] | p=1.00 | 0 | -18 | 1 | Gradishar, | | progression or death (progression free survival PFS) | 0.79 [0.56 1.11] | p=1.00 | 0 | -18 | 1 | Gradishar, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Gradishar, 2013 | paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) plus sorafenib (400mg, orally, twice daily) | paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) | first-line therapy in patients with HER2-negative advanced breast cancer |
|
| Sorafenib | renal-cell carcinoma (advanced), in all type of patients | vs interferon alpha | - | - | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.88 [0.61 1.27] | p=1.00 | 0 | 189 | 1 | Escudier, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Escudier, 2009 | oral sorafenib 400 mg twice daily | subcutaneous IFN--2a 9 million U three times weekly | patients with untreated, advanced renal cancer. |
|
| Sorafenib | renal-cell carcinoma (advanced), in all type of patients | vs placebo | - | NS | by 56% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.88 [0.74 1.04] | p=1.00 | 0 | 903 | 1 | TARGET, | | progression or death (progression free survival PFS) | 0.44 [0.35 0.55] | p=0.04 | 0 | 903 | 1 | TARGET, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TARGET, 2007 | continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) | placebo | patients with renal-cell carcinoma that was resistant to standard therapy | | Ratain, 2006 | | | patients with metastatic renal cell carcinoma |
|
| Lapatinib | advanced breast cancer (metastatic), in all type of patients | vs letrozole alone | by 100% | NS | by 29% [demonstrated] | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | 2.00 [1.57 2.55] | p=0.04 | 0 | 1286 | 1 | Johnston (EGF30008) , | | death (overall survival) | 0.78 [0.57 1.07] | p=1.00 | 0 | 1286 | 1 | Johnston (EGF30008) , | | progression or death (progression free survival PFS) | 0.71 [0.53 0.96] | p=0.04 | 0 | 1286 | 1 | Johnston (EGF30008) , | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Johnston (EGF30008) , 2009 | daily letrozole (2.5 mg orally) plus lapatinib (1,500 mg orally) | letrozole | hormone receptor-positive metastatic breast cancer |
|
| Lapatinib | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel alone | by 65% | NS | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | 1.65 [1.16 2.35] | p=0.04 | 0 | 579 | 1 | Di Leo, | | death (overall survival) | 0.86 [0.69 1.08] | p=1.00 | 0 | 579 | 1 | Di Leo, | | progression or death (progression free survival PFS) | 0.90 [0.75 1.08] | p=1.00 | 0 | 579 | 1 | Di Leo, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Di Leo, 2008 | first-line therapy with paclitaxel 175 mg/m(2) every 3 weeks plus lapatinib 1,500 mg/d | paclitaxel | first-line treatment for metastatic breast cancer |
|
| Apitolisib | renal-cell carcinoma (advanced), in all type of patients | vs everolimus | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Powles, 2014 | | | |
|
| Axitinib | renal-cell carcinoma (advanced), in all type of patients | vs sorafenib | - | - | by 34% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.67 [0.54 0.81] | p=0.04 | 0 | -18 | 1 | AXIS (Rini), | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| AXIS (Rini), 2011 | axitinib | | second-line therapy in patients with metastatic renal cell cancer | | Qin, 2012 | | | |
|
| Dovitinib | renal-cell carcinoma (advanced), in all type of patients | vs sorafenib | - | - | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.86 [0.72 1.03] | p=1.00 | 0 | 570 | 1 | GOLD, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| GOLD, | dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) | sorafenib (400 mg orally twice daily) | patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor |
|
| Pazopanib | renal-cell carcinoma (advanced), in all type of patients | vs placebo | - | NS | by 54% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.91 [0.71 1.16] | p=1.00 | 0 | 435 | 1 | VEG105192, | | progression or death (progression free survival PFS) | 0.46 [0.37 0.57] | p=0.04 | 0 | 417 | 2 | Sternberg, VEG105192, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Sternberg, 2010 | pazopanib | placebo | treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma | | VEG105192, 2010 | | | treatment-naive and
cytokine-pretreated patients with advanced renal cell carcinoma |
|
| Pazopanib | renal-cell carcinoma (advanced), in all type of patients | vs sunitinib | - | NS | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.91 [0.76 1.08] | p=1.00 | 0 | 1110 | 1 | COMPARZ, | | progression or death (progression free survival PFS) | 1.05 [0.90 1.22] | p=1.00 | 0 | 1110 | 1 | COMPARZ, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| COMPARZ, 2013 | continuous dose of pazopanib (800 mg once daily) | sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment) | patients with clear-cell, metastatic renal-cell carcinoma, first line |
|
| Sunitinib | renal-cell carcinoma (advanced), in all type of patients | vs interferon alpha | - | NS | by 58% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.82 [0.67 1.00] | p=1.00 | 0 | 750 | 1 | Motzer, | | progression or death (progression free survival PFS) | 0.42 [0.32 0.55] | p=0.04 | 0 | 750 | 1 | Motzer, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Motzer, 2007 | repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) | interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). | patients with previously untreated, metastatic renal-cell carcinoma |
|
| Sunitinib | renal-cell carcinoma (advanced), in all type of patients | vs sorafenib | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| SWITCH, | | | |
|
| Tivozanib | renal-cell carcinoma (advanced), in all type of patients | vs sorafenib | - | NS | by 20% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.25 [0.95 1.63] | p=1.00 | 0 | 517 | 1 | TIVO-1, | | progression or death (progression free survival PFS) | 0.80 [0.64 0.99] | p=0.04 | 0 | 517 | 1 | TIVO-1, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TIVO-1, 2013 | tivozanib | sorafenib | initial targeted therapy in patients with metastatic renal cell carcinoma |
|
| Cabozantinib | renal-cell carcinoma (advanced), in all type of patients | vs everolimus | - | by 33% | by 42% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.67 [0.51 0.89] | p=0.04 | 0 | 658 | 1 | METEOR, | | progression or death (progression free survival PFS) | 0.58 [0.45 0.75] | p=0.04 | 0 | 658 | 1 | METEOR, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| METEOR, 2015 | cabozantinib at a dose of 60 mg
daily | everolimus at a dose of 10 mg daily | patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy |
|
| Cabozantinib | renal-cell carcinoma (advanced), in all type of patients | vs sunitinib | - | - | by 34% | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.66 [0.46 0.95] | p=0.04 | 0 | 157 | 1 | CABOSUN, | | objective response (ORR) | no data | | progression (Time to progression TTP) | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CABOSUN, 2017 | cabozantinib (60 mg once per day) | sunitinib (50 mg once per day; 4 weeks on, 2 weeks off). | untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria |
|
